ILC Dover specialises in the design and production of solutions for the biopharmaceutical, pharmaceutical and medical device markets. Credit: Matej Kastelic / Shutterstock.com.

Ingersoll Rand has signed an agreement for the acquisition of ILC Dover from investment company New Mountain Capital for $2.325bn in cash upfront, expanding its presence in life sciences.

The acquisition also includes an earnout based on meeting specific operating efficiency metrics this year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ILC Dover specialises in the design and production of solutions for the biopharmaceutical, pharmaceutical and medical device markets.

With more than 2,000 employees, the company has a customer base of 11 engineering and production facilities in Asia, North America and Europe.

Ingersoll Rand will also set up a life sciences platform within its precision and science technologies (P&ST) segment.

The platform will integrate ILC Dover and the life science-focused brands of Ingersoll Rand including Air Dimensions, ILS, Thomas, Tricontinent, Welch and Zinsser Analytic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The platform will generate $700m, allowing Ingersoll Rand to further concentrate its growth and investment in the life sciences.

ILC Dover president and CEO Corey Walker will spearhead the new life sciences platform, reporting directly to Ingersoll Rand chairman and CEO Vicente Reynal.

The current P&ST segment head Santiago Arias Duval will continue reporting to Reynal and will be responsible for leading a second platform within the unit.

This platform will comprise the remaining P&ST businesses, representing revenue of $1bn.

The acquisition will close in the second quarter of 2024.

Reynal stated: “This acquisition is the next phase of our long-term vision to expand into higher-growth end markets like life sciences.

“We see many opportunities to leverage ILC’s established market positions and brands, including the ability to attach Ingersoll Rand’s existing liquid handling technologies and positive displacement pumps to ILC’s single-use solutions in key biopharma and pharma production processes.

“Through ILC, we will get access to approximately 1,000 customers in the broader life science and healthcare sectors, where we can leverage our demand generation capabilities to drive incremental growth in other Ingersoll Rand product lines like compressors.”